Beovu intravitreal injection kit 120mg/mL, manufactured by Novartis Pharma, contains brolucizumab (genetical recombination) and is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema (DME). This 6mg 0.05mL 1 cylinder formulation (YJ code: 1319406G1024) functions as a vascular endothelial growth factor (VEGF) inhibitor to prevent abnormal blood vessel formation and leakage in the eye.
Beovu intravitreal injection kit 120mg/mL
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →